Serum Inhibitors of Myxoviruses

  • Olga Križanová
  • Vojta Rathová
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 47)


The term “serum inhibitors of myxoviruses” has been used to designate proteinaceous substances differing from antibody and occurring in animal sera. These substances prevent agglutination of red blood cells by myxoviruses and at least some of them also inhibit reproduction of myxoviruses in susceptible cells.


Influenza Virus Sialic Acid Human Seron Mumps Virus Influenza Virus Strain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alexandrova, G. I.: An analysis of the structure of the populations of inhibitor-sensitive and inhibitor-resistant A2 influenza virus strains. Acta virol. 6, 487–497 (1962).Google Scholar
  2. Ananthanaryan, R., and C. J. K. Paniker: Non-specific inhibitors of influenza viruses in normal sera. Bull. Wld Hlth Org. 22, 409–420 (1960).Google Scholar
  3. Anderson, S. G.: Mucins and mucoids in relation to influenza virus action. Aust. J. exp. Biol. med. Sci. 26, 347–411 (1948).PubMedGoogle Scholar
  4. Bang, F. B., M. Foard, and D. T. Karzon: The determination and significance of substances neutralizing Newcastle Virus in human serum. Johns Hopk. Hosp. Bull. 87, 130–143 (1950).Google Scholar
  5. Bartolomei-Corsi, O., A. M. Casazza, A. di Marco, M. Ghione, and A. Zanella: Biological properties of a horse serum inhibitor against influenza A2 viruses. In VIIIth Int. Congr. Microbiol., Abstracts, Montreal, Quebec, Canada, No. D. 30. 5p. 96(1962).Google Scholar
  6. Bayer, M. E.: The reaction of receptor glycoprotein with influenza virus and neuraminidase. An electron microscopic study. Trans. N.Y. Acad. Sci. 26, Suppl. 1103–1111 (1965).Google Scholar
  7. Belyavin, G.: The mechanism of influenza virus haemagglutination as a model of specific receptor adsorption. J. gen. Microbiol. 32, 15–18 (1963).PubMedGoogle Scholar
  8. Belyavin, G., and A. Cohen: Chromatography of influenza virus haemagglutination inhibitors. Virology 18, 144–145 (1962).PubMedGoogle Scholar
  9. Biddle, F., D. S. Pepper, and G. Belyavin: Properties of horse serum gamma inhibitor. Nature (Lond.) 207, 381–383 (1965).Google Scholar
  10. Biddle, F., and K. F. Shortridge: Immunological cross-reactions of influenza virus inhibitors. Brit. J. exp. Path. 48, 285–293 (1967).Google Scholar
  11. Biddle, F., and J. P. Stevenson: Flocculation of influenza viruses by horse serum inhibitor. Nature (Lond.) 209, 1223–1225 (1966).Google Scholar
  12. Blaškovič, D., N. A. Maximovič, B. Styk, and P. Albrecht: Course of adaptation of the inhibitor-resistant influenza virus A2 to ferrets. Čs. Epidem. 10, 158–165 (1961) [in Slovak].Google Scholar
  13. Borecký, L.: A factor destroying virus receptors in pneumococcal cultures. I. Isolation and properties of the factor. Acta virol. 2, 73–83 (1958).PubMedGoogle Scholar
  14. Borecký, L.: Mechanisms of nonspecific resistance of the organism. Bratislava, Vydavatel’stvo Slovenskej akadémie vied 1967 [in Slovak].Google Scholar
  15. Borecký, L., S. Halperen, and W. W. Ackermann: Comparative study of the interaction of polyoma and other hemagglutinating viruses with an isolated bovine mucoprotein. J. Immunol. 89, 752–758 (1962a).PubMedGoogle Scholar
  16. Borecký, L., D. Kočišková, and L. Hána: An attempt to affect the level of serum inhibitors of myxoviruses in vivo. I. Effect of ethionine administration on the level of inhibitors in guinea-pig sera. Acta virol. 5, 236–244 (1961).Google Scholar
  17. Borecký, L., V. Lackovič, and V. Rathová: Surface properties of the egg and mouse lines of Al influenza virus. J. Immunol. 95, 387 (1965).PubMedGoogle Scholar
  18. Borecký, L., V. Lackovič, and V. Rathová, and E. Mrena: The syndrome of adaptation of influenza viruses to laboratory animals. J. Hyg. Epidem. (Praha) 10, 277–287 (1966).Google Scholar
  19. Borecký, L., and V. Rathová: Investigations of possible cross reactions between preparations of Salmonellae containing Vi antigen and inhibitors or antibodies against myxoviruses. Acta virol. 7, 339–349 (1963b).Google Scholar
  20. Borecký, L., and V. Rathová, and D. Kočišková: An attempt to affect the level of serum inhibitors of myxoviruses in vivo. II. Effect of ethionine administration on virus multiplication. Acta virol. 6, 97–104 (1962 c).Google Scholar
  21. Borecký, L., and V. Rathová, and D. Kočišková, and L. Hána: Effect of d-1 ethionine on some factors of nonspecific resistance to myxoviruses. J. Hyg. Epidem. (Praha) 6, 65–70 (1962b).Google Scholar
  22. Borecký, L., and V. Rathová, and O. Križanová: Nonspecific resistance of the organism and myxovirus inhibitors. (Comparison of some antibacterial and antiviral mechanisms.) Folia microbiol. (Praha) 8, 137–146 (1963 a).Google Scholar
  23. Boretti, G., A. Di Marco, and J. Piera: Preparation and characterization of an influenza virus inhibitor from horse serum. G. Microbiol. 12, 55–70 (1964).Google Scholar
  24. Bowarnick, M., and P. M. de Burgh: Virus haemagglutination. Science 105, 550 (1947).Google Scholar
  25. Brans, L. M., E. Hertzberger, and J. L. Binkhorst: Studies on the elimination of nonspecific inhibitor in sera against influenza viruses with the aid of filtrates of Vibrio Cholerae. Antonie v. Leeuwenhoek 19, 309 (1953).Google Scholar
  26. Briody, B. A.: Antigenic mutants of influenza virus. Fed. Proc. 16, 407–408 (1957).Google Scholar
  27. Briody, B. A., and W. A. Cassel: Adaptation of influenza virus to mice. I. Changes in the growth curve of an A prime strain of influenza virus. J. Immunol. 74, 37–40 (1955b).PubMedGoogle Scholar
  28. Briody, B. A., and W. A. Cassel, and M. A. Medill: Adaptation of influenza virus to mice. III. Development of resistance to beta-inhibitor. J. Immunol. 74, 41–45 (1955 a).PubMedGoogle Scholar
  29. Bürgi, W., and K. Schmid: Preparation and properties of Zn-alfa2-glycoprotein of normal human plasma. J. biol. Chem. 236, 1066–1077 (1961).PubMedGoogle Scholar
  30. Burnet, F. M., and J. D. Stone: The receptor-destroying enzyme of V. Cholerae. Aust. J. exp. Biol. med. Sci. 25, 227–235 (1947).PubMedGoogle Scholar
  31. Burnet, J. M.: The effect of periodate on the virus inhibitory qualities of mucoids in solution. Aust. J. exp. Biol. med. Sci. 27, 218 (1949).Google Scholar
  32. Burnet, J. M., and J. F. McCrea: Inhibitory and inactivating action of normal ferret sera against an influenza virus strain. Aust. J. exp. Biol. med. Sci. 24, 277–282 (1946).PubMedGoogle Scholar
  33. Casazza, A. M., A. di Marco, M. Ghione, and A. Zanella: Biological properties of a horse serum inhibitor against influenza A2 viruses. G. Microbiol. 12, 1–14 (1964).Google Scholar
  34. Choppin, P. W., and W. Stoeckenius: Interactions of ether-disrupted influenza A2 virus with erythrocytes, inhibitors, and antibodies. Virology 22, 482–492 (1964).PubMedGoogle Scholar
  35. Choppin, P. W., and I. Tamm: Two kinds of particles with contrasting properties in influenza A virus strains from the 1957 pandemic. Virology 8, 539–542 (1959).PubMedGoogle Scholar
  36. Choppin, P. W., and W. Stoeckenius: Studies of two kinds of virus particles which comprise influenza A2 virus strains. II. Reactivity with virus inhibitors in normal sera. J. exp. Med. 112, 921–944 (1960a).PubMedGoogle Scholar
  37. Choppin, P. W., and W. Stoeckenius: Studies of two kinds of virus particles which comprise influenza A2 virus strains. I. Characterization of stable homogeneous substrains in reactions with specific antibody, mucorpotein inhibitors and erythrocytes. J. exp. Med. 112, 895–920 (1960b).PubMedGoogle Scholar
  38. Chu, C. M.: The action of normal mouse serum on influenza virus. J. gen. Microbiol. 5, 739–757 (1951).PubMedGoogle Scholar
  39. Cohen, A.: Protection of mice against Asian influenza virus infection by a normal horse serum inhibitor. Lancet 1960b II, 791–794.Google Scholar
  40. Cohen, A., and G. Belyavin: Hemagglutination inhibition of Asian influenza viruses: A new pattern of response. Virology 7, 59–74 (1959).PubMedGoogle Scholar
  41. Cohen, A., and G. Belyavin: The influenza virus hemagglutination inhibitors of normal rabbit serum. I. Separation of the inhibitory components. Virology 13, 58–67 (1961).PubMedGoogle Scholar
  42. Cohen, A., and G. Belyavin, and E. Newland: Analysis of the horse serum inhibitor of A2 influenza virus haemagglutination and infectivity. VIIIth Int. Congr. Microbiol., Montreal, Quebec, Canada, No. D. 30. 4, p. 95 (1962).Google Scholar
  43. Cohen, A., and F. Biddle: The effect of passage in different hosts on the inhibitor sensitivity of an Asian influenza virus strain. Virology 11, 458–473 (1960a).PubMedGoogle Scholar
  44. Cohen, A., and F. Biddle: Haemagglutination inhibition. Interaction of influenza viruses with horse serum inhibitor. Nature (Lond.) 198, 508–509 (1963b).Google Scholar
  45. Cohen, A., and F. Biddle, and S. E. Newland: Analysis of horse serum inhibitors of A2 influenza virus haemagglutination. Brit. J. exp. Path. 46, 497–513 (1965a).PubMedGoogle Scholar
  46. Cohen, A., and J. Dorman: Non-specific inhibitors of A2 influenza virus in human sera. Actavirol. 9, 519–525 (1965b).Google Scholar
  47. Cohen, A., S. E. Newland, and F. Biddle: Inhibition of influenza virus haemagglutination: A difference of behavior in sera from a single species. Virology 20, 518–529 (1963 a).PubMedGoogle Scholar
  48. Davoli, R., and O. Bartolomei-Corsi: Nonspecific inhibition of the haemagglutination by influenza viruses. VI. Haemagglutination-inhibition and neutralization of infectivity of influenza viruses of the type A2 by normal guinea pig serum activated by heat. Sperimentale 109, 32–42 (1959).Google Scholar
  49. Dawson, P. S.: The nature of substances present in normal bovine sera inhibiting the activity of parainfluenza 3 virus. J. comp. Path. 73, 428–436 (1963).PubMedGoogle Scholar
  50. Expert committee on respiratory virus diseases. Wld Hlth Org. techn. Rep. Ser., No 170 (1959).Google Scholar
  51. Fauconnier, B., R. M.Lartitégui et D. Barua: Adaptation artificielle du virus grippal aux inhibiteurs du serum normal. I. Obtention, à partir d’une souche sensible d’une variante insensible par culture du virus en présence de son inhibiteur. Ann. Inst. Pasteur 97, 473–478 (1959).Google Scholar
  52. Fiset, P.: Serological techniques. In: Techniques in experimental virology. London and New York: R. J. C. Harris 1964.Google Scholar
  53. Francis, T., Jr.: Dissociation of hemagglutinating and antibody measuring capacities of influenza virus. J. exp. Med. 85, 1–7 (1947).PubMedGoogle Scholar
  54. Fridman, E. A.: Non-specific neutralization of influenza virus and methods for its removal. Thesis Leningrad 1955 [in Russian].Google Scholar
  55. Füresz, J.: Studies on inhibitors of influenza virus haemagglutination in normal rabbit and ferret sera. Canad. J. Microbiol. 5, 505–511 (1959).Google Scholar
  56. Gamburg, V. P.: Haemagglutination inhibitor and neutralizing factor of A2 influenza virus in sera. Acta virol. 5, 317–324 (1961).Google Scholar
  57. Geft, R. A., and R. Ya. Polyak: Removal of thermostable inhibitors against A2 influenza virus from immune horse sera by rivanol. Acta virol. 7, 91 (1963).Google Scholar
  58. Gibbons, R. A.: The sensitivity of the neuraminosidic linkage in mucosubstances towards acid and towards neuraminidase. Biochem. J. 89, 380–391 (1963).PubMedGoogle Scholar
  59. Ginsberg, H., and R. J. Wedgwood: Properdin and the inactivation of viruses. Ann. N.Y. Acad. Sci. 83, 528–532 (1960).PubMedGoogle Scholar
  60. Ginsberg, H. S., and F. L. Horsfall: A labile component of normal serum which combines with various viruses. Neutralization of infectivity and inhibition of hemagglutination by the component. J. exp. Med. 90, 475–495 (1949).PubMedGoogle Scholar
  61. Gorbunova, A. S., V. M. Stakhanova, A. N. Lozhkina, and V. D. Olli: Comparative efficacy of methods for treatment of sera with carbon dioxide, V. Cholerae filtrate and potassium periodate for eliminating unspecific inhibitors of hemagglutination to influenza A2 virus. Vop. Virus. 4, 750–753 (1959) [in Russian].PubMedGoogle Scholar
  62. Gorev, N. E.: The use of broth culture filtrates of Pseudomonas fluorescens for the destruction of non-specific thermostabile (at 56° C) influenza virus inhibitor in human sera. Acta virol. 2, 171–178 (1958).PubMedGoogle Scholar
  63. Gottschalk, A.: Chemistry of virus receptors. In: The viruses (F. M. Burnet and W. M. Stanley). New York and London 1959.Google Scholar
  64. Gottschalk, A.: The chemistry and biology of sialic acids and related substances. Cambridge 1960.Google Scholar
  65. Hána, L.: Some properties of haemagglutination inhibitor against influenza C virus. Proc. of the IVth Int. Congr. Biochem. Vienna 1958, 7, Sympos. 7, 160–162 (1958).Google Scholar
  66. Hána, L.: Non-specific inhibitors of myxoviruses. Zprávy z epidemiol. a mikrobiol. 5, 40–43 (1963a) [in Slovak].Google Scholar
  67. Hána, L., and B. Styk: Influence of delipidisation on the haemagglutination inhibiting activity of rat serum against influenza typ C viruses. Acta virol. 4, 392–393 (1960b).Google Scholar
  68. Hána, L., and B. Styk: Lipoids as inhibitors of heamagglutination-inhibiting activity against “avid” of A2 influenza. Acta virol. 5, 190–192 (1961).Google Scholar
  69. Hána, L., and B. Styk: An attempt to differentiate beta-inhibitor from cofactor occurring in bovine serum. Acta virol. 6, 77–83 (1962).PubMedGoogle Scholar
  70. Hána, L., and B. Styk, and D. Kočišková: Estimation of the distribution and the character of inhibitors against “avid” A2 influenza virus strains in protein fractions of guinea pig and horse sera obtained by paper electrophoresis. Acta virol. 4, 356–364 (1960a).Google Scholar
  71. Hána, L., and B. Styk, and Š. Schramek: Studies on the size of antibodies, cofactor and nonspecific inhibitors of influenza virus using separation on Sephadex G-200. Science Tools 10, 1–4 (1963 b).Google Scholar
  72. Harboe, A., and R. Reenaas: The course of antibody development to influenza A2 strains. Acta path. microbiol. scand. 46, 266–272 (1959).PubMedGoogle Scholar
  73. Harboe, A., and R. Reenaas, and M. Oppedal: Studies on Francis inhibitor of influenza virus hemagglutination in rabbit serum fractions obtained by electrophoresis on starch-grain. Acta path. microbiol. scand. 44, 92–105 (1958).PubMedGoogle Scholar
  74. Hollós, I.: The effect of modified Francis-inhibitors on reproduction of influenza virus. Acta microbiol. Acad. Sci. hung. 10, 82–83 (1963).Google Scholar
  75. Horváth, S.: Comparison of the experimental results obtained in the course of inactivation of non-specific inhibitors in serum by means of the haemagglutination and virus neutralization tests. Arch. ges. Virusforsch. 11, 295–303 (1961).PubMedGoogle Scholar
  76. Isaacs, A., and A. Bozzo: The use of V. cholerae filtrates in the destruction of non-specific inhibitor in ferret sera. Brit. J. exp. Path. 32, 325–335 (1951).PubMedGoogle Scholar
  77. Isachenko, V. A., G. A. Smirnova, and A. S. Gorbunova: Isolation of an inhibitor-sensitive variant from an inhibitor-resistant influenza A2 culture by gel-filtration with Sephadex. Vop. Virus. 10, 97–98 (1965) [in Russian].PubMedGoogle Scholar
  78. James, S. M., and P. Fiset: Serum inhibitors of Asian strains of influenza virus. Nature (Lond.) 184, Suppl. 21, 1656–1657 (1959).Google Scholar
  79. Jandásek, L.: Study of the interaction between the “transition strains” of influenza virus A2 and the inhibitor contained in the sera of normal guinea pigs. J. Hyg. Epidem. (Praha) 8, 44–48 (1964).Google Scholar
  80. Jandásek, L.: Inhibitoren des Influenzavirus. Arch. exp. Vet. Med. 21, 313–318 (1967).Google Scholar
  81. Jensen, K. E.: “Memorandum”. Communicable Disease Center, Montgomery, Alabama, 1958.Google Scholar
  82. Jandásek, L., and A. Montgomery: New set of type A influenza viruses. J. Amer. med. Ass. 164, 2025–2029 (1957).Google Scholar
  83. Jordan, W. S., and R. O. Ozeasohn: The use of RDE to improve the sensitivity of hemagglutination-inhibition test for the serologic diagnosis of influenza. J. Immunol. 72, 229–235 (1954).PubMedGoogle Scholar
  84. Karzon, D. T.: Non-specific viral inactivating substance (VIS) in human and mammalian sera. J. Immunol. 76, 454–463 (1956).PubMedGoogle Scholar
  85. Karzon, D. T., and R. H. Bussell: Studies of the nonspecific inactivation of Newcastle disease virus by mammalian sera. Ann. N.Y. Acad. Sci. 83, 539–550 (1960).PubMedGoogle Scholar
  86. Kathan, R. H., C. A. Johnson, and R. J. Winzler: On the glycoprotein inhibitor of viral hemagglutination from human erythrocytes. Acta Soc. Med. upsalien. 64, 290 (1959).Google Scholar
  87. Kathan, R. H., and R. J. Winzler: Structure studies on the myxovirus hemagglutination inhibitor of human erythrocytes. J. biol. Chem. 238, 21–25 (1963).Google Scholar
  88. Kathan, R. H., and R. J. Winzler, and C. A. Johnson: Preparation of an inhibitor of viral hemagglutination from human erythrocytes. J. exp. Med. 113, 37–45 (1961).PubMedGoogle Scholar
  89. Klein, M., and A. Deforest: A serum inhibitor in animal and human sera of bovine enteroviruses. II. In vivo activity and role in “natural” resistance to infection. J. Immunol. 92, 822–826 (1964b).PubMedGoogle Scholar
  90. Klein, M., G. Evans, A. Deforest, and B. Kleger: A serum inhibitor in animal and human sera of bovine enteroviruses. I. Properties and in vitro activity. J. Immunol. 95, 816–821 (1964a).Google Scholar
  91. Klein, M., G. Evans, and Y. Zellat: Properties of non-antibody inhibitor in the sera of man and other animals. Fed. Proc. 21, 461 (1962).Google Scholar
  92. Konno, J.: Beta-inhibitor, its biological and physico-chemical properties with particular emphasis on the differences from alfa-inhibitor, immune serum and properdin. Tohoku J. exp. Med. 67, 391–405 (1958).PubMedGoogle Scholar
  93. Kosyakov, P. N., M. S. Berdinskikh, and Z. I. Rovnova: Ability of viruses to overcome the action of inhibitors and antibodies. Vop. Virus. 7, 28–35 (1962b) [in Russian].Google Scholar
  94. Kosyakov, P. N., N. M. Gruzdeva, and M. S. Berdinskikh: The problem of the therapeutic effect of specific antibodies and inhibitors in influenza infection. Vop. Virus. 8, 301–307 (1963) [in Russian].Google Scholar
  95. Kosyakov, P. N., and Z. I. Rovnova: Virus-cell system exposed to specific antibody and inhibitors. VIIIth Int. Congr. for Microbiology, Abstracts, Montreal, Quebec, Canada, No. E 32 B. 12. p. 109 (1962a).Google Scholar
  96. Krasovskaya, I. A.: Changes in some properties of influenza A2 virus after treatment with sodium periodate. Vop. Virus. 9, 434–437 (1964) [in Russian].Google Scholar
  97. Krikszens, A. E.: Some chemical and physical characteristics of purified beta-inhibitor from bovine serum. Proc. Soc. exp. Biol. (N.Y.) 126, 176–181 (1967).Google Scholar
  98. Križanová, O., and J. Leško: Separation of gamma-inhibitor on carboxymethyl cellulose. Acta virol. 7, 179–182 (1964).Google Scholar
  99. Križanová, O., V. Rathová, D. Kočišková, and J. Szántó: The purification and some properties of the beta-inhibitor from bovine serum. Bratisl. lek. Listy 43, 22–29 (1963) [in Slovak].Google Scholar
  100. Križanová, O., and F. Sokol: Purification of bovine serum beta inhibitor by chromatographic methods and its reaction with Al influenza virus. Acta virol. 10, 35–42 (1966).PubMedGoogle Scholar
  101. Križanová-Laučíková, O., J. Szántó, and P. Albrecht: Localization of virus hemagglutination inhibitor in the chorioallantoic membrane. Virology 15, 501–503 (1961a).PubMedGoogle Scholar
  102. Križanová-Laučíková, O., J. Szántó, and D. Kočišková: Purification and some properties of the thermostable inhibitor against avid A2 influenza virus from horse serum. Acta virol. 5, 4–11 (1961b).PubMedGoogle Scholar
  103. Križanová-Laučíková, O., J. Szántó, and D. Kočišková, G. Ruttkay-Nedecký, and F. Sokol: Differences in the properties of two inhibitors avid A2 influenza virus strains from horse serum. Acta virol. 5, 12–18 (1961c).PubMedGoogle Scholar
  104. Laurell, A. B.: Inhibitor capacity of some purified human serum proteins on haemagglutination by influenza virus. Acta path. microbiol. scand. 49, 213–222 (1960).PubMedGoogle Scholar
  105. Levy, A. H., P. S. Norman, and R. R. Wagner: Electrophoresis of serum inhibitors of influenza viruses. Fed. Proc. 18, 580 (1959).Google Scholar
  106. Link, F., D. Blaškovič, and J. Raus: On the therapeutic effect of gamma inhibitor in mice infected with an inhibitor-sensitive unadapted A2 influenza virus. Acta virol. 9, 553 (1965).PubMedGoogle Scholar
  107. Link, F., J. Szántó, and O. Križanová: A quantitative assay of the in vivo protective effect of gamma inhibitor against inhibitor sensitive A2 influenza virus strain. Acta virol. 8, 71–75 (1964).PubMedGoogle Scholar
  108. Lippelt, H., u. W. Wirth: Unspezifische Hemmfaktoren im Meerschwein-Normalserum gegenüber Influenza-Viren. Arch. ges. Virusforsch. 9, 497–509 (1959).PubMedGoogle Scholar
  109. Lobodziňska, M., and O. Križanová: The relationship between hemagglutination and adsorption of influenza viruses on red blood cells of different animal species and their total sialic acid content. Arch. Immunol. Ter. dośw. 13, 631–638 (1965).Google Scholar
  110. Lobodziňska, M., and O. Križanová: Purification and properties of an influenza virus inhibitor isolated from mouse lungs. Acta virol. 10, 28–34 (1966).PubMedGoogle Scholar
  111. Luzyanina, T. Ya., and R. Ya. Polyak: Localization on the termolabile virus-neutralizing factors in the protein fractions of rabbit and guinea pig sera. Yearbook Institute of Experimental Medicine of the Academy of Medical Sciences of the USSR, 1957, p. 330–332. Leningrad 1958 [in Russian].Google Scholar
  112. Luzyanina, T. Ya., and R. Ya. Polyak, and A. A. Smorodintsev: Virus-neutralizing activity of non-specific thermolabile normal serum inhibitors against the myxovirus, adenovirus and enterovirus groups. Yearbook Institute of Experimental Medicine of the Academy of Medical Sciences of the USSR, 1960, p. 422–427. Leningrad 1961 [in Russian].Google Scholar
  113. Luzyanina, T. Ya., A. L. Salminen, and A.A. Smorodintsev: Peculiarities of the interaction of thermostable inhibitors from normal sera with type A2 influenza viruses of the 1957 pandemic Acta virol. 4, 137–145 (1960).Google Scholar
  114. Luzyanina, T. Ya., and A. A. Smorodintsev: Neutralization of mumps virus in chick embryo cell cultures. Acta virol. 9, 160–164 (1965).PubMedGoogle Scholar
  115. McCrea, J. F.: Nonspecific serum inhibition of influenza haemagglutination. Aust. J. exp. Biol. med. Sci. 24, 283–291 (1946).PubMedGoogle Scholar
  116. McCrea, J. F.: Mucins and mucoids in relation to influenza virus action. II. Isolation and characterization of the serum mucoid inhibitor of heated influenza virus. Aust. J. exp. Biol. med. Sci. 26, 355 (1948).PubMedGoogle Scholar
  117. Medill-Brown, M., and B. A. Briody: Mutation and selection pressure during adaptation of influenza virus to mice. Virology 1, 301–312 (1955).PubMedGoogle Scholar
  118. Meyer, H. M., Jr., M. R. Hilleman, M. L. Miesse, I. P. Cramford, and A. S. Bankhead: New antigenic variant in Far East influenza epidemic 1957. Proc. Soc. exp. Biol. (N.Y.) 95, 609–6l6 (1957).Google Scholar
  119. Morawiecki, A., and E. Lisowska: Polymerized orosomucoid an inhibitor of influenza virus hemagglutination. Biochem. biophys. Res. Commun. 18, 606–610 (1965).PubMedGoogle Scholar
  120. More virus inhibitors. (Leading articles.) Lancet 1961 I, 755–756.Google Scholar
  121. Mulder, J., de Novijer, and L. M. Blans: The influence of treating ferret influenza antisera with enzymes of crude filtrate of Vibrio cholerae on the titre of the antibodies. Antonie van Leeuwenhoek 18, 128 (1952).PubMedGoogle Scholar
  122. Nagase, M., and Y. Kabata: Possible destruction of antibody by treating human serum with KIO4. Studies on several inhibitors against influenza viruses. Virus (Jap.) 11, 65 (1961) [in Japan with English summary].Google Scholar
  123. Niculescu, I.: Inhibitors of influenza viruses. Microbiologia, parasitologia, epidemiologia (Rumun.) 10, 103–110 (1965) [in Rumunian].Google Scholar
  124. Odin, L.: Sialic acid in human serum protein and meconium. Acta chem. scand. 9, 862 (1955).Google Scholar
  125. Orsi, N.: Inhibitori naturali dell’infettività virale. Riv. Ist. sieroter. ital. 41, 77–91 (1966) [in Italian].PubMedGoogle Scholar
  126. Orsi, N., R. Calio, A. Stasio, and L. Sinibaldi: On the use of influenza virus strains sensitive to non-specific inhibitors in the hemagglutination-inhibition reaction. Riv. Ist. sieroter. ital. 42, 3–15 (1967).PubMedGoogle Scholar
  127. Petrov, K. Yu.: Effect on influenza virus of unspecific virus neutralizing substances in animal sera. Vop. Virus. 5, 167–172 (1960) [in Russian].PubMedGoogle Scholar
  128. Pichuskov, A. V.: Inhibitors of hemagglutination by parainfluenza virus types 1, 2, 3. Vop. Virus. 10, 74–78 (1965) [in Russian].Google Scholar
  129. Polyak, R. Ya., T. Ya. Luzyanina, and A. A. Smorodintsev: Biochemical investigation of influenza virus neutralizing protein fractions of sera from different animals. Acta virol. 3, 61–70 (1959).PubMedGoogle Scholar
  130. Polyak, R. Ya., and A.A. Smorodintsev: Electrophoretic investigations of thermostable inhibitors of type A2 influenza virus in normal animal sera. Acta virol. 5, 1–3 (1961).Google Scholar
  131. Rathová, V.: The possible role of inhibitor in non-specific defence of the organism. Zprávy z epidemiol. mikrobiol. (Praha) 5, 46–52 (1963) [in Slovak].Google Scholar
  132. Rathová, V.: (1965): Unpublished results.Google Scholar
  133. Rathová, V., L. Borecký, and D. Kočišková: An attempt to influence in vivo the serum levels of myxovirus inhibitors. III. The effect of the administration of some vitamins on inhibitors and some other serum factors in guinea pigs and mice. Bratisl. lek. Listy 43, 31–40 (1963) [in Slovak].Google Scholar
  134. Rathová, V., and D. Kočišková: Antibody response after different modes of administration of the influenza virus group A2 in some laboratory animals and the influence of different methods of removing non-specific inhibitors on the titre of specific antibodies in their sera. Čs. Epidem. 10, 170–175 (1961) [in Slovak].Google Scholar
  135. Rathová, V., and D. Kočišková, J. Szántó, O. Laučíková, and L. Hána: Some properties of the virus-neutralizing factor of normal animal sera. Vop. Virus 4, 717–723 (1959) [in Russian].PubMedGoogle Scholar
  136. Reimold, G.: Über die Wechselwirkung von Seruminhibitoren, Hühnererythrocyten und Influenzaviren. Z. Immun.-Forsch. 118, 121–134 (1959).Google Scholar
  137. Rovnova, Z. I., and P. N. Kosyakov: Inhibitors and antibodies in the course of immunization of animals with viral preparations. Acta virol. 11, 69–77 (1967).Google Scholar
  138. Rykowska, R., and L. Sawicki: The gamma-inhibitor of normal horse serum. II. The protective properties of the serum and its fractions against infection of mice and tissue cultures with the Singapore strains of influenza virus. Med. dosw. Mikrobiol. 15, 47–54 (1963) [in Polish].PubMedGoogle Scholar
  139. Sampaio, A. A. C.: Inhibitors of influenza virus haemagglutination in normal animal sera. Bull. Wld Hlth Org. 6, 467–472 (1952).Google Scholar
  140. Sampaio, A. A. C., and A. Isaacs: The action of trypsin on normal serum inhibitors of influenza virus agglutination. Brit. J. exp. Path. 34, 152–158 (1953).Google Scholar
  141. Sawicki, L., and R. Rykowska: The guinea pig and white rat serum inhibitors as a possible factor of natural resistance of these animals to infection with certain strains of influenza virus. Med. došw. Mikrobiol. 15, 55–64 (1963) [in Polish].PubMedGoogle Scholar
  142. Schmidt, B., K. Grossgebauer u. D. Hartmann: Über die Enzymaktivität äthergespaltener Influenzaviren und ihren Einfluß auf unspezifische Seruminhibitoren. Z. Immun.-Forsch. 120, 238–248 (1960).Google Scholar
  143. Shimizu, N., and N. Ishida: The characteristics of both hemagglutinin inhibitors and growth inhibitory substances of influenza viruses found in animal specimens. Tohoku J. exp. Med. 67, 390 (1958).PubMedGoogle Scholar
  144. Shimojo, H., A. Sugiura, J. Akao, and Ch. Enomoto: Studies of a non-specific hemagglutination inhibitor of influenza A (Asian) 57 virus. Bull. Inst. Publ. Health 7, 219–224 (1958).Google Scholar
  145. Shiratori, T., M. Nagase, H. Kudo, T. Kikawa, and Y. Kabata: Characterization of non-specific hemagglutinin inhibitors detectable in the sera of experimental animals. Virus (Jap.) 11, 162–163 (1961).Google Scholar
  146. Simkin, J. L., E. R. Skinner, and H. S. Seshadri: Studies on an acidic glyco-protein-containing fraction isolated from guinea-pig serum. Biochem. J. 90, 316–330 (1964).PubMedGoogle Scholar
  147. Smith, W., and J. C. N. Westwood: Influenza virus haemagglutination. The mechanism of the Francis phenomenon. Brit. J. exp. Path. 31, 725–738 (1950).PubMedGoogle Scholar
  148. Smith, W., and J. C. N. Westwood, and G. Belyavin: Influenza: A study of four virus strains isolated in 1951. Lancet 1951 II, 1189.Google Scholar
  149. Smith, W., and M. A. Westwood: Factors involved in influenza haemagglutination reactions. Brit. J. exp. Path. 30, 48–61 (1949).PubMedGoogle Scholar
  150. Smorodintsev, A. A.: Factors of natural resistance and specific immunity to viruses. Virology 3, 299–321 (1957).PubMedGoogle Scholar
  151. Smorodintsev, A. A., and T. Ya. Luzyanina: Interaction of the thermolabile fractions of normal sera from various animals and the virulent and avirulent strains of the influenza virus. Yearbook Inst. of exp. Med. of the Acad. Med. Sci. USSR, 1957, p. 326–330, Leningrad 1958 [in Russian].Google Scholar
  152. Smorodintsev, A. A., and O. I. Šiškina: The effect of normal laboratory animal sera on influenza virus. Zh. Mikrobiol. (Mosk.) 22, 16–19 (1951) [in Russian].Google Scholar
  153. Springer, G. F.: Human MN glycoproteins: Dependence of blood-group and anti-influenza virus activities on their molecular size. Biochem. biophys. Res. Commun. 28, 510–513 (1967).PubMedGoogle Scholar
  154. Stone, J. D.: Inhibition of influenza virus hemagglutination by mucoids. II. Differential behaviour of mucoid inhibitors with indicator viruses. Aust. J. exp. Biol. med. Sci. 27, 557 (1949).Google Scholar
  155. Stone, J. D.: Adsorptive and enzymatic behaviour of influenza virus during the O-D change. Brit. J. exp. Path. 32, 367–376 (1951).PubMedGoogle Scholar
  156. Stulberg, C. C., R. Schapira, A. R. Robinson, D. H. Basinski, and H. A. Freund: Inhibition of influenza virus hemagglutination by purified plasma mucoproteins. Proc. Soc. exp. Biol. (N.Y.) 76, 704–706 (1961).Google Scholar
  157. Styk, B.: Non-specific inhibitors in normal rat serum for the influenza C type virus. Fol. biol. (Praha) 1, 207–213 (1955).Google Scholar
  158. Styk, B.: Inhibitors of the influenza virus in human sera after passaging in volunteers. Acta virol. 1, 238–239 (1957).PubMedGoogle Scholar
  159. Styk, B.: Sensibilization by means of potassium periodate of inhibitor-resistant A2 influenza virus strains to non-specific serum inhibitors. Nature (Lond.) 193, 954–955 (1962a).Google Scholar
  160. Styk, B.: Effect of some inhibitor-destroying substances on the non-specific inhibitor of C influenza virus present in normal rat serum. Acta virol. 7, 88–89 (1963).Google Scholar
  161. Styk, B., L. Hána, F. Franěk, F. Sokol, and J. Menšík: Investigations on cofactor and influenza antibodies by density gradient zonal centrifugation. Acta virol. 6, 478 (1962 b).PubMedGoogle Scholar
  162. Sugiura, A., H. Shimojo, and C. Enomoto: Studies of the non-specific hemagglutination inhibitor against influenza A2 virus (gamma-inhibitor). II. Physicochemical properties of the gamma-inhibitor. Jap. J. exp. Med. 31, 159–168 (1961 a).PubMedGoogle Scholar
  163. Sugiura, A., H. Shimojo, and C. Enomoto: Studies of the non-specific hemagglutination inhibitor against influenza A2 virus. III. Destruction of gamma-inhibitor by virus enzyme. Jap. J. exp. Med. 31, 169–177 (1961 b).PubMedGoogle Scholar
  164. Szántó, J., O. Križanová, and F. Link: Interaction of gamma-inhibitor with A2 influenza virus. Acta virol. 6, 524–530 (1962).Google Scholar
  165. Takátsy, G., and K. Barb: On the normal serum inhibitors for the avid Asian strains of influenza virus. Acta virol. 3, (Suppl.) 71–79 (1959).PubMedGoogle Scholar
  166. Topciu, V., P. Diosi, E. Moldovan, O. Nevinglovschi, and G. Bran: Serological survey concerning the presence of influenza hemagglutination inhibitors in normal dog sera. Acta virol. 11, 55–57 (1967).PubMedGoogle Scholar
  167. Topciu, V., E. Moldovan, O. Nevinglovschi, N. Rosiu, and P. Diosi: Serological investigations on influenza inhibitors in domestic and wild animals. Rev. Roum. Infra-microbiol. 3, 271–276 (1966).Google Scholar
  168. Toussaint, A. J., and L. H. Muschel: Neutralization of bacteriophage by normal serum. Nature (Lond.) 183, 1825–1827 (1959).Google Scholar
  169. Tyrrell, D. A. J.: Separation of inhibitors of hemagglutination and specific antibodies for influenza viruses by starch zone electrophoresis. J. Immunol. 72, 494–502 (1954).PubMedGoogle Scholar
  170. Voláková, N., and L. Jandásek: A thermostable inhibitor of newly isolated influenza strains in guinea pig serum. Acta virol. 3, 109–112 (1959).PubMedGoogle Scholar
  171. Voluyskaya, E. N., V. I. Tovarnicky, and A. M. Byelikova: The effect of the properdin system on the influenza virus. J. Hyg. Epidem. (Praha) 2, 404–407 (1958).Google Scholar
  172. Wagner, R. R.: A pantropic strain of influenza virus: Generalized infection and viremia in the intact mouse. Virology 1, 497–515 (1955).PubMedGoogle Scholar
  173. Wenner, H. A., A. Monley, and M. K. Jensen: A study of infections caused by mumps and NDV viruses. II. Some properties of specific and nonspecific serum hemagglutination inhibitor components. J. Immunol. 68, 357–368 (1952).PubMedGoogle Scholar
  174. Werner, G. H., R. Sharma, and L. Gogolski: Hemagglutinin inhibition with ether-treated antigen as a more sensitive method to measure the immunological response to an Asian influenza virus vaccine. Arch. ges. Virusforsch. 10, 7–18 (1960).PubMedGoogle Scholar
  175. Whitehead, P. H.: Viral inhibition by polymerized orosomucoid. Biochem. J. 95, 8P (1965).Google Scholar
  176. Whitehead, P. H., T. H. Flewet, J. R. Foster, and H. G. Sammons: Inhibition of influenza virus haemagglutination by polymerized orosomucoid. Nature (Lond.) 208, No 5013, 915–916 (1965).Google Scholar
  177. Yakhno, M. A.: Influence of inhibitor-destructive treatment on influenza antibody. Vop. Virus. 6, 334–335 (1961) [in Russian].Google Scholar
  178. Zakstelskaya, L. Y., and M. A. Yakhno: The sensitivity of different strains of A2 influenza virus to the action of inhibitors occurring in animal sera. Vop. med. Virus. (Mosk.) 5, 71–73 (1958) [in Russian].Google Scholar
  179. Zhdanov, V. M., V. P. Gamburg, and G. J. Svet-Moldavsky: Antigenicity of the inhibitor of influenza virus strain A (Asie) 57. J. Immunol. 82, 9–12 (1959).PubMedGoogle Scholar
  180. Zhdanov, V. M., L. J. Zakstelskaya, V. E. Jefimova, M. A. Yakhno, and S. L. Khait: Antigenic peculiarities of 1957 influenza viruses and serologic indexes of immunity among the population. J. Amer. med. Ass. 167, 1469–1474 (1958).Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1969

Authors and Affiliations

  • Olga Križanová
    • 1
  • Vojta Rathová
    • 1
  1. 1.Institute of VirologyCzechoslovak Academy of SciencesBratislavaSlovakia

Personalised recommendations